Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
暂无分享,去创建一个
M. Goldman | F. Bethoux | A. Goodman | A. Blight | E. Carrazana | A. Mayadev | M. Klingler | Angela Applebee
[1] M. Goldman,et al. Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial. , 2015, International journal of MS care.
[2] R. Motl,et al. Accelerometry as a measure of walking behavior in multiple sclerosis , 2013, Acta neurologica Scandinavica.
[3] Frances Lynn,et al. Timed 25-Foot Walk , 2013, Neurology.
[4] A. Blight,et al. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis , 2011, Current medical research and opinion.
[5] L. Dibble,et al. Ambulatory Activity in Individuals With Multiple Sclerosis , 2011, Journal of neurologic physical therapy : JNPT.
[6] L. Krupp,et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis , 2010, Annals of neurology.
[7] L. Krupp,et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial , 2009, The Lancet.
[8] Jeffrey A. Cohen,et al. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls , 2008, Multiple sclerosis.
[9] Jaana Paltamaa,et al. Measuring Deterioration in International Classification of Functioning Domains of People With Multiple Sclerosis Who Are Ambulatory , 2008, Physical Therapy.
[10] A J Thompson,et al. Measuring the impact of MS on walking ability , 2003, Neurology.
[11] N. Larocca. Impact of Walking Impairment in Multiple Sclerosis , 2011, The patient.